Cost-effectiveness and long-term outcomes of liver transplantation using hepatitis B core antibody-positive grafts with hepatitis B immunoglobulin prophylaxis in Korea
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Hepatitis B core antibody (anti-HBc)-positive donors are used as an extended donor pool, and current guidelines recommend the usage of nucleos(t)ide analogues (NAs) as prophylaxis for preventing de novo hepatitis B virus infection (DNH). We analyzed the long-term outcomes of a large cohort of liver transplantation (LT) patients receiving anti-HBc-positive grafts and evaluated the risk of DNH when hepatitis B immunoglobulin (HBIG) monotherapy was used as prophylaxis. We also compared the cost-effectiveness of HBIG and NAs. Methods: We retrospectively reviewed 457 patients with anti-HBc-positive grafts and 898 patients with anti-HBcnegative grafts who underwent LT between January 2001 and December 2018. We compared recipient characteristics according to the anti-HBc status of the donor, and compared the costs of using NAs for the rest of the patient’s life and using HBIG to maintain hepatitis B surface antibody titers above 200 IU/L. Results: The 1-, 5-, and 10-year patient survival rates were 87.7%, 73.5%, and 67.7%, respectively, in patients with anti- HBc-positive grafts, and 88.5%, 77.4%, and 70.3%, respectively, in patients with anti-HBc-negative grafts (P=0.113). Among 457 recipients with anti-HBc-positive grafts, 117 (25.6%) were non-HBV recipients. The overall incidence of DNH was 0.9%. When using HBIG under insurance coverage, the cumulative cost was lower compared with using NA continuously without insurance coverage in Korea. Conclusions: Anti-HBc-positive grafts alone do not affect patient survival or graft survival. HBIG monoprophylaxis has good outcomes for preventing DNH, and the patient’s long-term cost burden is low in Korea because of the national insurance system in this cohort.
Abstract
Background/Aims: Hepatitis B core antibody (anti-HBc)-positive donors are used as an extended donor pool, and current guidelines recommend the usage of nucleos(t)ide analogues (NAs) as prophylaxis for preventing de novo hepatitis B virus infection (DNH). We analyzed the long-term outcomes of a large cohort of liver transplantation (LT) patients receiving anti-HBc-positive grafts and evaluated the risk of DNH when hepatitis B immunoglobulin (HBIG) monotherapy was used as prophylaxis. We also compared the cost-effectiveness of HBIG and NAs. Methods: We retrospectively reviewed 457 patients with anti-HBc-positive grafts and 898 patients with anti-HBcnegative grafts who underwent LT between January 2001 and December 2018. We compared recipient characteristics according to the anti-HBc status of the donor, and compared the costs of using NAs for the rest of the patient’s life and using HBIG to maintain hepatitis B surface antibody titers above 200 IU/L. Results: The 1-, 5-, and 10-year patient survival rates were 87.7%, 73.5%, and 67.7%, respectively, in patients with anti- HBc-positive grafts, and 88.5%, 77.4%, and 70.3%, respectively, in patients with anti-HBc-negative grafts (P=0.113). Among 457 recipients with anti-HBc-positive grafts, 117 (25.6%) were non-HBV recipients. The overall incidence of DNH was 0.9%. When using HBIG under insurance coverage, the cumulative cost was lower compared with using NA continuously without insurance coverage in Korea. Conclusions: Anti-HBc-positive grafts alone do not affect patient survival or graft survival. HBIG monoprophylaxis has good outcomes for preventing DNH, and the patient’s long-term cost burden is low in Korea because of the national insurance system in this cohort.
참고문헌 (23)
- Chazouillères O, ""Occult" hepatitis B virus as source of infection in liver transplant recipients", Lancet, 343, pp.142~146 (1994)
- Dickson RC, "Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database", Gastroenterology, 113, pp.1668~1674 (1997)
- Takemura N, "Liver transplantation using hepatitis B core antibody-positive grafts : review and university of Tokyo experience", Dig Dis Sci, 52, pp.2472~2477 (2007)
- Korean Association for the Study of the Liver (KASL), "KASL clinical practice guidelines for management of chronic hepatitis B", Clinical and Molecular Hepatology, 25(2), pp.93~159 (2019), 대한간학회
- Lee KW, "Prevention of de novo hepatitis B infection from HbcAb-positive donors in living donor liver transplantation", Transplant Proc, 36, pp.2311~2312 (2004)
- Huprikar S, "Solid organ transplantation from hepatitis B virus-positive donors : consensus guidelines for recipient management", Am J Transplant, 15, pp.1162~1172 (2015)
- European Association for the Study of the Liver, "EASL clinical practice guidelines : liver transplantation", J Hepatol, 64, pp.433~485 (2016)
- Yang Y, "Effect of hepatitis B surface antibody in patients with core antibody-positive liver transplantation : a systematic review and meta-analysis", Hepatol Int, 14, pp.202~211 (2020)
- Lee S, "De novo hepatitis b prophylaxis with hepatitis B virus vaccine and hepatitis B immunoglobulin in pediatric recipients of core antibody-positive livers", Liver Transpl, 22, pp.247~251 (2016)
- Donataccio D, "Use of anti-HBc positive allografts in adult liver transplantation : toward a safer way to expand the donor pool", Transpl Int, 19, pp.38~43 (2006)
- Roque-Afonso AM, "Antibodies to hepatitis B surface antigen prevent viral reactivation in recipients of liver grafts from anti-HBC positive donors", Gut, 50, pp.95~99 (2002)
- Lei M, "Safety of hepatitis B virus core antibody-positive grafts in liver transplantation : a single-center experience in China", World J Gastroenterol, 24, pp.5525~5536 (2018)
- Yamashiki N, "The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of anti-HBc-positive livers", Pediatr Transplant, 22, pp.e13227~ (2018)
- Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
- Prieto M, "De novo hepatitis B after liver transplantation from hepatitis B core antibody-positive donors in an area with high prevalence of anti-HBc positivity in the donor population", Liver Transpl, 7, pp.51~58 (2001)
- Burton JR Jr, "Use of hepatitis B core antibodypositive donors in recipients without evidence of hepatitis B infection : a survey of current practice in the United States", Liver Transpl, 9, pp.837~842 (2003)
- Brandl A, "Inferior graft survival of hepatitis B core positive grafts is not influenced by post-transplant hepatitis B infection in liver recipients--5-year single-center experience", Transpl Int, 29, pp.471~482 (2016)
- MacConmara MP, "Utilization of hepatitis B core antibody-positive donor liver grafts", HPB(Oxford), 14, pp.42~48 (2012)
- 한재현, "De novo hepatitis B virus infection developing after liver transplantation using a graft positive for hepatitis B core antibody", Annals of Surgical Treatment and Research, 89(3), pp.145~150 (2015), 대한외과학회
- Wong TC, "Liver transplantation using hepatitis B core positive grafts with antiviral monotherapy prophylaxis", J Hepatol, 70, pp.1114~1122 (2019)
- Cholongitas E, "Liver grafts from anti-hepatitis B core positive donors : a systematic review", J Hepatol, 52, pp.272~279 (2010)
- Saab S, "Comparison of different immunoprophylaxis regimens after liver transplantation with hepatitis B core antibody-positive donors : a systematic review", Liver Transpl, 16, pp.300~307 (2010)
- Wright AJ, "Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers : a cost-effectiveness analysis", Am J Transplant, 14, pp.629~634 (2014)